DECHRA PHARMACEUTICALS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,866 GBX | -.--% |
|
-.--% | +0.21% |
| Sales 2022 | 682M 852M 71.01B | Sales 2023 | 762M 951M 79.31B | Capitalization | 4.2B 5.24B 437B |
|---|---|---|---|---|---|
| Net income 2022 | 58M 72.45M 6.04B | Net income 2023 | -27M -33.73M -2.81B | EV / Sales 2022 | 5.8 x |
| Net Debt 2022 | 208M 260M 21.68B | Net Debt 2023 | 430M 537M 44.8B | EV / Sales 2023 | 6.08 x |
| P/E ratio 2022 |
64.8
x | P/E ratio 2023 |
-150
x | Employees | - |
| Yield 2022 |
1.3% | Yield 2023 |
0.34% | Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 6 months | +2.55% | ||
| Current year | +0.21% |
Current year
3 853.34
3 868.00
1 year
3 060.004 145.84
3 years
2 473.325 525.00
5 years
2 030.005 525.00
10 years
664.005 525.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ian Page
CEO | Chief Executive Officer | 63 | 13/97/13 |
Paul Sandland
DFI | Director of Finance/CFO | 44 | 01/10/01 |
Jamie Adams
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ian Page
CEO | Chief Executive Officer | 63 | 13/97/13 |
Geeta Gopalan
BRD | Director/Board Member | 59 | 01/23/01 |
Alison Platt
CHM | Chairman | - | 01/20/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 8.11% | 1 M€ | -.--% | ||
| 0.08% | 773 M€ | -.--% | - |
Dechra Pharmaceuticals PLC specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows:
- companion animal products (74.6%);
- food producing animal products (11.5%);
- equine health products (7.3%);
- animal feeds (5.1%);
- other (1.5%): products manufactured by third parties.
Net sales are distributed geographically as follows: the United Kingdom (8.5%), Germany (9.2%), Europe (31.2%), the United States (37.9%) and other (13.2%).
Sector
-
- Stock Market
- Equities
- DPH Stock
